News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
73–76
Matches
76
Sources here
1
Companies here
1
Search results Stored financial headlines

Active search

76 matching headlines

Ticker or company: A1ZN34Main company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

finance.yahoo.com Market update Main company 🇧🇷 Brazil

Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune

Royalty Pharma plc NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a portion of Neurimmune's royalty interest in AstraZeneca's cliramitug for up to $425 million, including $125 million upfront. Cliramitug is a Phase …

A1ZN34 main company
Sharemaestro market context Price below Trend Line 52 weeks -6.1% · Next-week setup positive 58.4% A1ZN34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Astrazeneca (AZN) Falls More Steeply Than Broader Market: What Investors Need to Know

Astrazeneca (AZN) closed at $164.52 in the latest trading session, marking a -2.59% move from the prior day. This change lagged the S&P 500's 0.19% loss on the day. Elsewhere, the Dow lost 0.59%, while the tech-heavy Nasdaq lost 0.05%. The pharmaceutical's stock has …

A1ZN34 main company
Sharemaestro market context Price below Trend Line 52 weeks -6.1% · Next-week setup positive 58.4% A1ZN34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Market update Main company 🇧🇷 Brazil

Merck’s Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over.

For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as Merck Keytruda, the best-selling drug in the world. Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form …

A1ZN34 main company
Sharemaestro market context Price below Trend Line 52 weeks -6.1% · Next-week setup positive 58.4% A1ZN34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Market update Main company 🇧🇷 Brazil

What Comes After Merck’s Keytruda? The Race for the Next Standard Cancer Treatment.

For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as Merck Keytruda, the best-selling drug in the world. Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form …

A1ZN34 main company
Sharemaestro market context Price below Trend Line 52 weeks -6.1% · Next-week setup positive 58.4% A1ZN34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context